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Abstract
Objective: To analyze cytokine levels in BAL fluid of patients with bronchiectasis due to mustard
gas inhalation.
Patients: 29 victims with mustard gas-induced bronchiectasis and 25 normal veterans as control
group.
Intervention: PFTs,, high-resolution CT scans of the chest, analyses of BAL fluids for five
cytokines (IL-8, IL-1β, IL-6, TNF-α, IL-12) and analyses of BAL fluids for cellular and flow-
cytometric analysis of the phenotype of bronchoalveolar cells were performed in all cases.
Results: CD4 lymphocytes expressed as percentage or absolute number were significantly higher
in patients with bronchiectasis than in controls (32.17 ± 16.00 vs 23.40 ± 6.97%, respectively; p =
0.01; and 3.31 ± 2.03 vs 1.88 ± 0.83 × 103 cells/ml, respectively; p = 0.001). The CD4/CD8 ratio
was significantly higher in patients with bronchiectasis than in controls (3.08 ± 2.05 vs 1.68 ± 0.78;
p = 0.002).
There were significant differences in cytokine (IL-8, IL-1β, IL-6, TNF-α, IL-12) levels of BAL fluid
between patients with bronchiectasis and healthy controls.
A significant correlation was observed between the HRCT scores and both the percentage and the
absolute number of CD4 lymphocytes in BAL fluid in patients with bronchiectasis (r = -0.49, p =
0.009; r = -0.50, p = 0.008; respectively). HRCT scores showed a significant correlation with CD4/
CD8 ratios (r = 0.54, p = 0.004) too.
Of measured BAL cytokines, only IL-8 (r = -0.52, p = 0.005) and TNF-aα (r = 0.44, p = 0.01) showed
significant correlations with the HRCT scores.
Conclusion: The increased levels of cytokines CD4 lymphocytes in the BAL fluid suggest the
possible causative mechanism in the lung in sulfur mustard gas-induced bronchiectasis by the
recruitment of neutrophils into the lung.
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The toxicity of the chemical warfare blistering agent sulfur
mustard (2,2'-dichlorodiethyl sulfide; SM) has been
investigated for nearly a century [1,2]. This toxic gas can
damage the eyes and respiratory tract when present in
high doses [3].
Bronchiectasis, a chronic supportive lung disease charac-
terized by irreversible dilatation of the bronchi and per-
sistent suppurative sputum production, is a well-known
late complication of sulfur mustard gas exposure in
human [4]. Although the respiratory tract lesions repre-
sent the major debility after sulfur mustard exposure, only
a few studies have investigated the pathophysiology of
sulfur mustard-induced respiratory diseases, in particular
the mechanisms involved in inflammatory processes.
T-lymphocytes have an essential role in many types of
inflammatory response. It could, therefore, be anticipated
that the lymphocytes may also play a role in the response
to inhaled mustard gas. We undertook this study to inves-
tigate the role of T cell and proinflammatory cytokines in
patients with bronchiectasis due to sulfur mustard gas
inhalation. This study was designed to analyze bronchoal-
veolar lavage lymphocyte subsets and to determine the
ratio of CD4 to CD8 lymphocytes in BAL fluid in these
veterans with bronchiectasis. The levels of cytokines in
patients having bronchiectasis were further studied to cor-
relate with the disease severity expressed as HRCT scores.
Methods
Patient population
Of all the veterans admitted to our university teaching
hospital in 1986 with a single heavy exposure to sulfur
mustard gas, 29 male patients with bronchiectasis were
enrolled into this study. The patients' exposure to sulfur
mustard gas had been confirmed by studies on their urine
and vesicular fluid in 1986. The etiology of bronchiectasis
was post-sulfur-mustard gas inhalation. Patients were
characterized as having bronchiectasis based on a history
consistent with the disease and a computed tomographic
(CT) scan of the chest showing pathological changes con-
sistent with bronchiectasis [5]. All patients had a persist-
ent cough and daily sputum production. All of the
patients were lifetime nonsmokers.
All cases had bilateral bronchiectasis. Patients were
excluded from the study if they had suffered an exacerba-
tion of their symptoms during the preceding 4 weeks.
None of the 29 patients had received antibiotic therapy or
oral steroids within the four week period preceding the
study.
None of the patients had any evidence of connective tissue
disorders, sarcoidosis, eosinophilic granuloma, pneumo-
coniosis, carcinomatosis, or lymphoma. They signed a
written informed consent form and underwent a thor-
ough history and physical examination. A chest roentgen-
ogram, an ECG, and a high-resolution CT (HRCT) of the
chest were obtained in each patient. Approval was
obtained from the local ethics committee. This study was
done in 2005.
Measurement of pulmonary function tests (PFTs)
Pulmonary function tests were performed. These tests
were measured through spirometric assessment according
to the standards advocated by the American Thoracic Soci-
ety [6]. Prior to bronchoscopy, an experienced physician
did all spirometric measurements (FUDAC 50; Fukunda
Sangyo; Chiba, Japan) in all patients and subjects. Each
patient was well trained to give his best effort. After 15
min of resting, three spirometric measurements were
done at 1-min intervals; the highest values measured were
reported. Results were expressed as percentage predicted
based on accepted reference standards [7,8].
High-resolution computed tomographic examination
The HRCT scans were done with 1- to 1.5-mm sections
taken at 1-cm intervals through the entire thorax and were
reconstructed using a bone algorithm. The HRCT scans of
the patients was assessed and scored by the same consult-
ant pulmonary radiologist, who was blinded to all other
details concerning the patient. Each lobe of both lungs
was graded for bronchiectasis changes on a 0–3 scale (the
lingula was scored as a separate lobe), giving a maximum
of 18 points: 0: no bronchiectasis; 1: one or no bronchop-
ulmonary segment involved; 2: more than one bronchop-
ulmonary segment involved; and 3: gross cystic
bronchiectasis [9].
Healthy control subjects
The control group consisted of 25 normal, healthy non-
smoking veterans with a mean (± SD) age of 37.37 ± 4.56
years old (range, 29 to 48 years old); the control subjects
had participated in the Iran-Iraq War but had not been
exposed to mustard gas. All subjects voluntarily entered
the study and signed an informed consent form before
their enrollment. All subjects had a complete history and
physical examination. No subjects had a history of expo-
sure to organic or inorganic dusts. In addition to obtain-
ing a chest radiograph, HRCT scan and an ECG for each
subject, PFTs were measured prior to bronchoscopy as
well. Asymptomatic healthy control subjects had no evi-
dence of chronic disease or airflow obstruction and spiro-
metric test results were within normal limits. The
examination of BAL cells and the determination of T cells
and cytokine levels were carried out for all cases using the
same techniques as described for the patients group.Page 2 of 11
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All of the patients underwent a bronchoscopic examina-
tion. Before any lung biopsy specimens were taken, BAL
was performed using a flexible fiberoptic bronchoscope
(Olympus BF1T; Tokyo, Japan). The lavages were col-
lected this year (20 years after exposure). Each patient was
premedicated with atropine (0.75 mg IM) before the pro-
cedure. Mild sedation was achieved with intravenously
administered midazolam, and supplementary oxygen was
given throughout the procedure. Patient oxygenation was
monitored by pulse oximetry. After applying 4% ligno-
caine spray to the nose and throat of the patient, the flex-
ible bronchoscope was introduced. Local anesthesia of the
larynx was achieved with topical 4% lignocaine, whilst a
2% solution was used below the vocal cords to suppress
coughing. The bronchoscope was wedged for lavage in the
middle lobe segmental bronchus, and four 60-ml aliquots
of sterile physiologic saline solution warmed to 37°C
were infused. The fluid was immediately recovered by
gentle suction after each instillation. The first aliquot
reflecting a bronchial sample was discarded, while the
others were pooled for our study. One milliliter of recov-
ered lavage fluid was processed for bacterial and fungal
culture by routine methods. Then, the BAL fluid was
passed through monolayer surgical gauze to eliminate
mucus. One small aliquot of this fluid was utilized to
count the total cell number, and another aliquot was spun
in a cytometer at 400 revolutions/min for 10 min. The cell
pellet was washed once in Hanks' balanced salt solution
(without calcium and magnesium). A May-Grünwald-
Giemsa stain smear was used to identify the differential
profiles after cytospin preparation. Total cell counts were
determined with a hemocytometer. The differential cell
count of lymphocytes, neutrophils, macrophages, and
eosinophils was made under light microscopy × 1,000 by
counting approximately 300 cells in a random field. The
result was expressed as cells × 103/ml. The unconcentrated
supernatant was frozen at -70°C before the protein was
measured.
Flow-cytometric analysis of the phenotype of 
bronchoalveolar cells
In order to identify the proportions of T lymphocytes,
CD4, CD8 T cells, B cells and natural killer (NK) cells sub-
populations of BAL fluid, cells were simultaneously
stained with fluorescein isothiocyanate or (FITC) and
phycoerythrin-conjugated (PE) monoclonal antibodies
(anti-IgG1, -IgG2a, -CD3, -CD4, -CD8, -CD19, -CD56)
(Beckon Dickinson, Mountain View, CA) according to the
manufacturer's protocol. The relative ratio of CD4 or CD8
in CD3-positive cells was assayed by a dual-color analysis.
Data were obtained and analyzed using Becton Dickinson
BD LYSYS II and Cytometric Bead Array (CBA) software
(San Jose, CA).
Measurement of the BAL cytokines
The levels of cytokines in BAL fluid were assayed using
Becton Dickinson (BD) Cytometric Bead Array™ (CBA; BD
Biosciences, San Jose, CA) [10] according to manufac-
turer's instructions with an antibody (PharMoingen, San
Diego, CA) against one of the five cytokines (Human
Inflammation Kit: IL-8, IL-1β, IL-6, TNF-α, IL-12, BD Bio-
sciences). The lower limits of detection of the kit (sup-
plier's data) were as follows: TNF-α, 0.085 pg/ml; IL-1β,
0.083 pg/ml; IL-6, 0.080 pg/ml; IL-8, 3.0 pg/ml, and IL-
12, 1.9 pg/ml.
Statistical analyses
Data are presented as mean ± SD unless otherwise stated.
Comparisons were made using the Mann-Whitney non-
parametric test for continuous data and by x2 analysis for
discontinuous data. Correlations between different
parameters were determined by Spearman's rank correla-
tion coefficient. P < 0.05 was considered significant.
Results
Demographics
The characteristics of the population are summarized in
Table 1. The age of the two groups did not significantly
differ (p = 0.37). HRCT scores showed a mean bronchial
dilatation (± SD) score of 9.37 ± 147 (range, 6 to 11). No
control subject had an obstructive or restrictive pattern in
his PFTs.
BAL fluid cellular constituents
Bacterial agents were classified into microorganisms with
potential pathogenicity (MPP) or microorganisms with
nonpotential pathogenicity, as described elsewhere (34).
Only microorganisms with potential pathogenicity (MPP)
with counts of ≥ 103 cfu × ml-1 in BALF were regarded as
significant. The pathogens recovered from BALF of
patients with bronchiectasis were P. aeruginosa (no = 2),
Haemophilus influenzae (no = 3), Serratia marcescens
(no = 1), and S. aureus (no = 2). Culture results in the con-
trol group showed negative.
The cellular contents of BAL fluids in both groups are
shown in Table 2. Patients with bronchiectasis had a
higher total cell count than the normal group, but it was
not significant (p = 0.31). When compared to healthy
controls, total and differential cell counts in patients with
bronchiectasis showed, an increase both of neutrophil
percentage (p < 0.0001) and neutrophil absolute number
(13.69 ± 3.26 versus 2.04 ± 1.06 × 103 cells/ml; p <
0.0001).
On comparison of the airway inflammatory characteris-
tics between patients with bronchiectasis colonized by
MPP (n = 8) and non-colonized patients with bron-
chiectasis (n = 21), we observed that the group of patientsPage 3 of 11
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and percentage, and a higher BALF concentration of IL-8.,
although the differences did not reach statistical signifi-
cance (Table 3). We observed that patients with bron-
chiectasis and negative cultures for MPP in the BALF had
a more intense inflammatory reaction than did control
subjects, with a higher percentage of neutrophils and
higher concentrations of IL-8 and other cytokine profiles
in BALF (Table 3).
Lymphocyte absolute number showed a week significant
increase in bronchiectasis patients when compared to
healthy controls (p < 0.04). The absolute number of alve-
olar macrophages, however, was significantly lower in
patients with bronchiectasis than in the control group (p
< p = 0.0005, respectively).
Lymphocyte subsets in BAL Fluid
The summarized results of the lymphocyte phenotyping
in the BALF of both the control and patients with bron-
chiectasis are observed in Table 4.
In patients with bronchiectasis there were increased abso-
lute numbers of CD3 T lymphocytes compared with nor-
mal controls (4.82 ± 1.81 versus 3.72 ± 1.62 × 103 cells/
ml, respectively; p = 0.02), while the percentage of CD3
cells showed no significant difference between the two
groups (48.15 ± 13.34 versus 46.39 ± 15.03; p = 0.65).
The profile of T-cell subtypes showed that when data were
expressed as percentage or as absolute number of positive
cells, CD4 lymphocytes were significantly higher in
patients with bronchiectasis than in healthy controls
(32.17 ± 16.00 versus 23.40 ± 6.97%, respectively; p =
0.01; and 3.31 ± 2.03 versus 1.88 ± 0.83 × 103 cells/ml,
respectively; p = 0.001). The proportion of CD8 cells in
BAL fluid was significantly diminished in patients with
bronchiectasis compared to the control group (11.84 ±
4.41 versus 15.76 ± 6.84; p = 0.01), while the absolute
number of CD8 cells showed no significant difference
between the two groups (1.13 ± 0.35 versus 1.16 ± 0.37; p
= 0.82).
Consequently, the CD4/CD8 ratio was significantly
higher in patients with bronchiectasis than in healthy
controls (3.08 ± 2.05 versus 1.68 ± 0.78; p = 0.002).
When B and NK (neural killer) alveolar lymphocytes were
evaluated either as a percentage or as absolute number, no
significant differences were found between the patients
with bronchiectasis and the control group (See Table 4).
Comparison of BAL fluid cellular constituents with HRCT 
scores
A significant positive correlation was observed between
HRCT scores and both the percentage and the absolute
number of neutrophils in BAL fluid in patients with bron-
chiectasis (r = -0.55, p = 0.003; r = -0.59, p = 0.001; respec-
tively) (Fig 1). No correlation was found between HRCT
scores and the other BAL cells.
Comparison of BAL Lymphocyte subpopulations with 
HRCT scores
A significant positive correlation was observed between
the HRCT scores and both the percentage and the absolute
number of CD4 lymphocytes in BAL fluid in patients with
Table 2: Comparison of bronchoalveolar lavage fluid cellular constituents of bronchiectasis due to sulfur mustard gas inhalation versus 
the control group*
Controls (n = 25) Bronchiectasis (n = 29) p Value
Recovery of BAL fluid, ml 160.48 ± 12.64 155.44 ± 17.28 0.23
Number of cells (× 103) 88.96 ± 7.59 91.89 ± 12.65 0.31
Macrophages (× 103) 78.00 ± 8.24 67.62 ± 11.79 0.0005
Lymphocytes (× 103) 8.40 ± 3.50 10.00 ± 2.08 0.04
Neutrophils (× 103) 2.04 ± 1.06 13.69 ± 3.26 < 0.0001
Eosinophils (× 103) 0.52 ± 0.58 0.58 ± 0.68 0.70
* Values are mean ± SD.
Table 1: Characteristics of the 29 bronchiectasis patients and 25 healthy subjects enrolled in the study*
Controls (no = 25) Bronchiectasis (no = 29) p Value
Age (years), mean ± SD 36.24 ± 4.78 37.37 ± 4.56 0.37
HRCT score*, mean ± SD 0.00 ± 0.00 9.37 ± 147 < 0.0001
HRCT score*, range 0 ± 0 6 ± 11 -
FEV1, % of predicted 97.53 ± 4.76 71.82 ± 6.52 < 0.0001
* Values are mean ± SD.Page 4 of 11
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respectively) (Fig 2). HRCT scores showed a significant
correlation with CD4/CD8 ratios (r = 0.54, p = 0.004) too.
No correlation was found between HRCT scores and the
other BAL cells.
Cytokine levels in BAL fluid samples
The BAL fluid levels of the cytokines (IL-8, IL-1β, IL-6,
TNF-α, IL-12) were found to be significantly elevated in
patients of bronchiectasis when compared with controls
(p < 0.0001) (Table 5).
Comparison of HRCT scores and cytokine levels in BAL 
fluid
Of measured BAL cytokines, only IL-8 (r = -0.52, p =
0.005) and TNF-α (r = 0.44, p = 0.01) showed significant
correlations with the HRCT scores (Fig 3).
Association between airway inflammation and FEV1
There was no significant difference in FEV1 between those
with or without detectable infection (p = 0.66). FEV1 (per-
centage predicted) correlated negatively with both the
number and the percentage of neutrophils (r = 0.53, p =
0.004) and IL-8 levels in BAL fluid of patients with bron-
chiectasis (r = 0.39, p = 0.03). A significant negative corre-
lation was also observed between the FEV1 (percentage
predicted) and both the percentage and the absolute
number of CD4 lymphocytes in BAL fluid in these
patients (r = 0.50, p = 0.007; r = -0.41, p = 0.02; respec-
tively). FEV1 (% predicted) showed a negative significant
correlation with CD4/CD8 ratios too (r = 0.40, p = 0.03).
There was no apparent correlation between the other dif-
ferent inflammatory parameters evaluated in the BAL
fluid and the FEV1 (percentage predicted) in patients with
bronchiectasis (data not shown).
Discussion
Bronchiectasis is the major cause of disability and mortal-
ity in mustard victims [4,11]. The main aim of this study
was to compare both levels of BAL lymphocyte subpopu-
lations and cytokines with the HRCT scores in patients
with bronchiectasis due to sulfur mustard gas inhalation.
To the best of the authors' knowledge, this is the first study
in which BAL Lymphocyte subpopulations and cytokine
levels have been evaluated in these victims with bron-
chiectasis.
This study revealed that patients with bronchiectasis,
when compared to healthy subjects, were characterized by
an increase in neutrophils in BAL fluid (Table 1). A posi-
tive correlation between either the percentage or the abso-
lute number of BAL fluid neutrophils and the HRCT
Table 4: Lymphocyte subpopulations in bronchoalveolar lavage from patients with bronchiectasis due to mustard gas exposure and 
normal subjects*
Controls (n=25) Bronchiectasis (n=29) p Value
CD3 cells (%) 46.39 ± 15.03 48.15 ± 13.34 0.65
CD3 cells (103 cells/ml) 3.72 ± 1.62 4.82 ± 1.81 0.02
CD4 cells (%) 23.40 ± 6.97 32.17 ± 16.00 0.01
CD4 cells (103 cells/ml) 1.88 ± 0.83 3.31 ± 2.03 0.001
CD8 cells (%) 15.76 ± 6.84 11.84 ± 4.41 0.01
CD8 cells (103 cells/ml) 1.16 ± 0.37 1.13 ± 0.35 0.82
CD4/CD8 (ratio) 1.68 ± 0.78 3.08 ± 2.05 0.002
B cells (%) 5.56 ± 6.76 3.58 ± 5.55 0.24
B cells (103 cells/ml) 0.52 ± 0.58 0.31 ± 0.47 0.15
NK cells (%) 2.83 ± 6.34 1.49 ± 3.86 0.34
NK cells (103 cells/ml) 0.20 ± 0.40 0.13 ± 0.35 0.55
* Values are mean ± SD.
Table 3: Total differential cell and neutrophil counts and IL8 concentrations from the BAL fluid of patients with bronchiectasis with or 
without microorganisms with potential pathogenicity (MPP) *
Control Subjects Noncolonized Patients Colonized Patients
Subjects, no 25 8 21
Number of cells (× 103) 88.96 ± 7.59 91.86 92.00‡
Neutrophils (× 103) 2.04 ± 1.06 14.54† 16.63‡
Neutrophils, % 2.33 ± 1.29 13.09† 15.25‡
IL-8 (pg/ml) 1.04 ± 1.17 35.86† 41.75‡
* Values are mean ± SD.
† p = 0.05 comparing control subjects versus noncolonized patients
‡ p = 0.05 comparing colonized and noncolonized patientsPage 5 of 11
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strated (Fig 1). These data also clearly demonstrate that
the degree of lung function impairment closely related to
neutrophilic alveolitis in patients with bronchiectasis. It
might act as a triggering factor in the development of
bronchiectasis in mustard gas-exposed patients. The large
numbers of neutrophils present in airspaces of the lung in
post-sulfur-mustard gas inhalation bronchiectasis may be
Relationship between the percentage and absolute number of CD4 lymphocytes in BAL fluid and the HRCT scores in patients with bronchiectasis due to mustard gas inhalationFigure 2
Relationship between the percentage and absolute number of CD4 lymphocytes in BAL fluid and the HRCT scores in patients 
with bronchiectasis due to mustard gas inhalation. There were significant, positive correlations between the percentage (r = -
0.49, p = 0.009) of and the absolute number of CD4 lymphocytes (r = -0.50, p = 0.008) in BAL fluid and HRCT scores.
Relationship between the percentage and absolute number of neutrophils in BAL fluid and the HRCT scores in patients with bronchiectasis due to mustard gas inh lationFigure 1
Relationship between the percentage and absolute number of neutrophils in BAL fluid and the HRCT scores in patients with 
bronchiectasis due to mustard gas inhalation. There were significant, positive correlations between the percentage (r = -0.55, p 
= 0.003) and the absolute number of neutrophils (r = -0.59, p = 0.001) in BAL fluid and HRCT scores.Page 6 of 11
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tion (See Table 2 and Table 3). This study showed positive
BAL fluid cultures in only 8 patients. Interestingly, our
findings suggest that airway inflammation may occur even
in the absence of colonization as demonstrated by the sig-
nificant increase in levels of the different inflammatory
mediators between patients with negative BAL cultures
and control subjects (Table 3). This study may confirm the
presence of airway neutrophilia, despite negative cultures
for the usual bronchiectasis-associated pathogens, sug-
gesting that inflammation may even precede infection
(See Table 3). In other words, quantitative bacteriological
cultures in this study may clarify the role of a previous
mustard gas exposure. Among the different cell types
involved in the airway inflammation, neutrophils are rec-
ognized to play a central role by releasing proinflamma-
tory mediators, such as reactive oxygen species and
proteolytic enzymes [37]. It is suggested that infection and
inflammation become intimately linked in the course of
the disease, with each exacerbating the other. Thus, a
vicious circle of infection and inflammation is established
that is mainly responsible for progressive and irreversible
lung damage in our patients with bronchiectasis. The find-
ing of this study (neutrophilic inflammation) is similar to
those described for patients with cystic fibrosis (CF) in the
literature [35]. The activated neutrophils are the primary
effector cells for the pathogenesis of CF lung disease
[36,37].
Analysis of T-lymphocyte subsets in BAL fluid indicates
that, in patients with bronchiectasis due to mustard gas
exposed, both the percentage and total numbers of CD4 T
cells increase and the percentage of CD8 T cells decreases
(See Table 4). This study on BAL fluid has also shown that
the CD4/CD8 ratio is significantly increased in patients
with bronchiectasis (Table 4).
CD8 or CD4 T cells infiltrate the lung in many clinical
conditions. An increase of T lymphocytes in airways in
patients with cystic fibrosis (CF) has been documented
Table 5: Cytokine levels in bronchoalveolar lavage from normal subjects and patients with bronchiectasis*
Controls (n=25) Bronchiectasis (n=29) p Value
IL-8 (pg/ml) 1.04 ± 1.47 37.48 ± 16.65 < 0.0001
IL-6 (pg/ml) 0.003 ± 0.01 2.53 ± 0.93 < 0.0001
IL-12 (pg/ml) 0.00 ± 0.00 1.90 ± 0.51 < 0.0001
IL-1β (pg/ml) 0.00 ± 0.00 3.71 ± 1.27 < 0.0001
TNF-α (pg/ml) 0.003 ± 0.01 1.30 ± 0.38 < 0.0001
* Values are mean ± SE.
Relationship between the IL-8 and TNF-α levels in BAL fluid and the HRCT scores in patients with bronchiectasis caused by mus ard gas inhalationFigure 3
Relationship between the IL-8 and TNF-α levels in BAL fluid and the HRCT scores in patients with bronchiectasis caused by 
mustard gas inhalation. There were significant, positive correlations between the IL-8 (r = -0.52, p = 0.005) and TNF-α (r = -
0.44, p = 0.01) in BAL fluid and HRCT scores.Page 7 of 11
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cells in the respiratory tract of HIV-infected children with
bronchiectasis, pattern of gene expression could be
changed in respiratory epithelium, leading to parenchy-
mal damage by a complex of infectious and inflammatory
reactions [38]. Activation of CD8+ cells in the airway of
patients with diffuse panbronchiolitis has been also doc-
umented [39]. A predominant CD4+ T cell infiltrate in the
bronchial mucosa in bronchiectasis patients has been
observed [40].
Mustards are very lipophilic and can therefore penetrate
epithelial tissues easily. The cellular damage and death is
thought to be mediated via the alkylation of DNA, which
leads to DNA strand breaks and apoptosis [41]. Human
cells exposed in culture to mustard gas show concentra-
tion dependent decreases in cell proliferation, DNA syn-
thesis, protein synthesis and NAD+ and ATP levels [42].
The clinical manifestations of mustard gas exposure result
from multiple mechanisms, although the exact pathways
are not yet elucidated [43]. The columnar cells of the epi-
thelial lining of the upper respiratory tract in an acute
heavy exposure may be damaged by this toxic warfare gas.
The shedding of the columnar cells may be accompanied
by peribronchial edema, hyperemia of the blood vessels,
cellular infiltrations in the submucosa and serious vacu-
olization and disorganization of cytoplasma and nuclear
structures [44]. These reactions may result in physiologi-
cal, metabolic and genetic failure of cellular functions. As
it has been shown in this study, these may cause an
inflammatory infiltrate (mostly T-lymphocytes and neu-
trophils) in the airways. In addition to T cells, other
inflammatory cell types such as neutrophils and macro-
phages are probably essential in the initial inflammatory
process leading to the breakdown of lung tissue, perhaps
producing peptides eventually recognized by T cells as
antigenic. This would provide an explanation for the T-
cell inflammation. Once activated, T cells are present in
the lung, and their effector functions would include the
attraction and enhancement of the inflammatory function
in other inflammatory cells like neutrophils and macro-
phages. Additionally, activation of several proteases and
proinflammatory cytokines is involved in sulphur mus-
tard injury.
However, the stimuli and the mechanisms that mediate
CD4 T-cell recruitment to the lung of our patients with
bronchiectasis are not understood. How CD4 T cells,
which are recruited to the lungs of these patients, are trig-
gered to express their effector functions, and how these
functions are downregulated, also is not known precisely.
But it is possible that injury to the airways epithelium,
which is the first structure encountered by sulfur mustard
gas, promotes and perpetuates inflammation in the air-
ways. It is likely that the alkylation of DNA and the shed-
ding of epithelial cells promote an initial neutrophilic
inflammation that by diverse mechanisms (eg, proteases
or oxidation) damages lung cells. Airway injury may lead
to structural alterations in self-antigens that create par-
tially cross-reactive neoantigens and to the release of ana-
tomically sequestered antigens that would be recognized
by autoreactive T cells, thereby inducing their activation
and proliferation [45,46]. It is possible that direct tissue
damage from sulfur mustard gas inhalation, known to
cause antigen release. It may be also hypothesized that in
patients with sulfur mustard gas-induced bronchiectasis
an excessive recruitment of CD4 T lymphocytes may occur
in response to recurrent or persistent bacterial infections,
and this excessive response may play a role for the devel-
opment of lung damage. Regardless of how the inflamma-
tory process is initiated and the temporal relationship
between infection and inflammation in sulfur mustard
gas-induced bronchiectasis, this study shows that persist-
ent inflammatory response in the airways plays a central
role in the progression of lung damage.
It should be emphasized that in this study, CD4+ T lym-
phocytes are the predominant lymphocyte cells involved
(See Table 4), whereas in COPD, CD8+, T lymphocytes,
and macrophages are predominantly involved [47]. Com-
parison of results of this study with those patients with
sulfur mustard gas-induced pulmonary fibrosis reveals,
that CD8 T cells in BAL fluid were surprisingly signifi-
cantly elevated in patients with pulmonary fibrosis (The
methods of both studies are similar to each other) [48].
The observed variability in terms of CD4 and CD8 T lym-
phocytes are possibly linked to a number of factors such
as: the concentration of inhaled toxin, the site of deposi-
tion of the toxin in the respiratory system, presence of
infections, and differences in patient's vulnerability and
susceptibility to the toxin.
We measured the relationship between T-lymphocyte sub-
sets and HRCT scores in the patients with bronchiectasis
due to mustard gas inhalation. The percentage and the
absolute number of CD4 T cells highly correlated with the
percentage of HRCT scores (r = -0.49, p = 0.009; r = -0.50,
p = 0.008; respectively) (See Fig 2). Therefore, we present
a set of observations that reveal that patients with more
advanced lung function impairment as HRCT pathologi-
cal findings, tended to reveal higher CD4/CD8_ratios.
Therefore, It is possible that increased CD4 T cells in the
BAL fluid may contribute to parenchymal destruction and
therefore to the development of repeated exacerbations in
these patients by releasing cytokines capable of increasing
the susceptibility of target cells to cytotoxicity, or by
secreting chemokines that attract other cells to the site of
inflammation [12,13]. The significant correlation
observed in our veterans between increased number of
CD4 T cells in the BAL fluid and the HRCT scores supportsPage 8 of 11
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for cell mediated immune mechanisms in the pathogene-
sis of ongoing airways damage in sulfur mustard gas-
induced bronchiectasis.
It has been showed that cytokines produced by bronchial,
bronchiolar, alveolar epithelial cells, alveolar macro-
phages and neutrophils are involved in the inflammatory
response [14,15]. The equilibrium between the proin-
flammatory cytokines tumour necrosis factor (TNF-α), IL-
12, IL-8, IL-6 and anti-inflammatory cytokines such as IL-
10 is essential for directing the immune response [16,17].
It is apparent from the present findings that the levels of
the pro-inflammatory cytokines increased significantly in
patients with bronchiectasis compared with healthy con-
trols (p < 0.0001) (Table 5). A significant elevation in IL-
8 was seen between these groups. Significantly elevated
levels of proinflammatory IL-6, TNF-α, and IL-12 were
likewise noted in cases with bronchiectasis versus healthy
controls.
Recruitment of neutrophils may lead to an increased and
persistent inflammatory state in the alveolar region. It is
likely that neutrophil accumulation in the BAL fluid of
patients with bronchiectasis is driven by increased release
of cytokines exerting a chemotactic effect on these cells.
This suggests a key role for these cytokines in neutrophil
influx into lung tissue and sustaining the intense local
inflammatory response in the affected bronchial tree [13].
Tumor necrosis factor-α (TNF-α) is a proinflammatory
cytokine predominantly released by macrophages and
monocytes but also other cells produce TNF-α such as
neutrophils and lymphocytes [18-20]. A role for in ampli-
fying the inflammation of COPD has been suggested [52].
TNF-α has a broad spectrum of inflammatory effects rele-
vant to COPD, resulting in activation of neutrophils,
monocytes, macrophages, epithelium, mucus secretion,
and destruction of lung parenchyma through release of
proteinases [52]. TNF-α is known to stimulate various
cells, including alveolar macrophages, for increased IL-8
production [21]. These observations, together with our
finding of the elevation of IL-8 in BAL fluid in sulfur mus-
tard gas-induced bronchiectasis patients, suggest that IL-8
plays an important role in the cell accumulation seen in
the lung in this disease (Table 5). TNF-α is also a chemo-
tactic agent for neutrophils [22]. In the cytokine network
model in the lung, alveolar cells initially respond to a
stimulus by secreting TNF-α and/or IL-1β. These cytokines
then act in an autocrine or paracrine fashion, leading to
IL-6 and IL-8 release and triggering an inflammatory
response. On the other hand, IL-6 has been shown that it
inhibits apoptosis [23]. Therefore, inefficient clearance of
apoptotic cells results in secondary necrosis of cells and
exacerbation of the inflammatory response [24]. Several
cytokines known to stimulate IL-6 release include IL-1,
TNF-α [25].
The participation of IL-8 has been reported in various dis-
eases and conditions [26-28]. Among the recruitment fac-
tors for neutrophils IL-8 is by far the most potent (29).
Since IL-8 can activate neutrophils by increasing degranu-
lation and neutrophil elastase release, our attention has
been focused on its pivotal and fundamental responsibil-
ity for bronchial destruction in bronchiectasis due to sul-
fur mustard gas inhalation [30].
Significant increased BAL fluid IL-8 level in patients with
bronchiectasis could be related to the neutrophilic inflam-
matory response and alveolitis observed in response to
acute massive inhalation of sulfur mustard gas (Table 5).
The significant correlations between the concentration of
IL-8 and either both, absolute count of and the percentage
of neutrophils in BALF (p = 0.03 and p = 0.04, respec-
tively) (data not mentioned in result) and the HRCT
scores may approve this relationship (See Fig 3).
IL-12 is a heterodimeric cytokine that plays a key role in
determining the nature of immune response to exogenous
or endogenous antigens [31]. It can activate inflammatory
cells like T cells, natural killer cells and can induce
cytokines such as interferon-γ, which in turn promotes IL-
12 production and macrophage activation [31,32]. An
overabundance of TNF-α or IL-12 is correlated with the
development of the inflammatory activity and the tissue
damage. In this study, the positive correlation between
the TNF-α levels in BAL fluid and the HRCT scores in
patients with bronchiectasis caused by mustard gas inha-
lation may approve this hypothesis (See Fig 3).
An early response to inhaled toxins, organic material, and
inorganic material is the recruitment of macrophages to
the lung, where they undergo phagocytosis and, if possi-
ble, destroy unwanted irritants. Macrophages in BAL fluid
from the lungs of smokers and those patients with COPD
are elevated many fold [49]. Furthermore, there is a posi-
tive association between macrophage numbers in the
alveolar walls and the presence of mild-to-moderate
emphysema as well as the degree of small airways disease
in patients with COPD [49].
COPD is characterized by chronic obstruction of expira-
tory flow affecting peripheral airways, often associated
with chronic bronchitis (mucus hypersecretion with gob-
let cell and submucosal gland hyperplasia) and emphy-
sema (destruction of airway parenchyma). Tissue damage
with airway wall remodeling and thickening, inflamma-
tion and fibrosis of the small airways appear to play an
important role in patients with COPD. Increased numbersPage 9 of 11
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bronchoalveolar lavage fluid and induced sputum from
such patients, and in the small airways, there is a mucosal
increase in the numbers of CD8 T-cells. Alveolar macro-
phages play a significant and important role in inflamma-
tion in chronic obstructive pulmonary disease. The
numbers of alveolar macrophages are markedly increased
in the lungs of patients with COPD as a result of increased
recruitment, proliferation and survival. In COPD, alveolar
macrophages produce many inflammatory mediators,
oxidants, proteins and proteinases in response to cigarette
smoke extract and other stimuli. Macrophage numbers in
the airways correlate with the severity of COPD [50-52].
In our study, a negative correlation between the FEV1 (%
predicted) and both the percentage and the absolute
number of macrophages may support the concept that the
role of the macrophage in sulfur mustard gas-induced
bronchiectasis may be marginal for the pathologic conse-
quences in our veterans with bronchiectasis. On the other
hand, our results showed that neutrophil numbers and
percentages are directly related to the % FEV1 (% pre-
dicted). Therefore, it may be suggested that the neutrophil
is a major player in our veterans who developed bron-
chiectasis.
The mainstay in pulmonary therapy of these patients
bases on physiotherapy (bronchial clearing) inhalations
[application of a variety of medications (bronchodilators,
antibiotics, steroids)], and enteral or parenteral antibiot-
ics to fight against bronchial infections. Macrolide treat-
ment is now considered to be effective for diffuse
panbronchiolitis (DPB), cystic fibrosis primarily through
the inhibition of neutrophil accumulation in the lung
[53-55]. The results of studies show that low- dose mac-
rolide may improve respiratory symptoms in sulfur mus-
tard injured patients too [56,57]. Therefore, the use of
azithromycin or erythromycin clarithromycin on a long-
term basis for infection control and inflammation modu-
lation is suggested.
In conclusion, CD4 T cells in BAL fluid were significantly
elevated in patients with bronchiectasis. Patients with
higher grades of bronchial destruction expressed as HRCT
scores, revealed higher percentages and the absolute
number of CD4 T cells and a higher CD4/CD8 ratio. This,
coupled with high levels of inflammatory mediators sug-
gests that sulfur mustard gas-induced bronchiectasis is an
ongoing inflammation. Our study also showed that, even
in the absence of an exacerbation, there is a marked
increase in the levels of cytokine in the BAL fluid.
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